Index -
P/E -
EPS (ttm) -2.21
Insider Own 35.44%
Shs Outstand 80.50M
Perf Week 0.12%
Market Cap 2.21B
Forward P/E -
EPS next Y -1.51
Insider Trans -0.06%
Shs Float 55.83M
Perf Month 0.87%
Income -190.42M
PEG -
EPS next Q -0.51
Inst Own 61.99%
Short Float 5.68%
Perf Quarter 54.72%
Sales 174.91M
P/S 12.65
EPS this Y 12.69%
Inst Trans 1.28%
Short Ratio 1.71
Perf Half Y 69.81%
Book/sh 3.85
P/B 6.65
EPS next Y 24.70%
ROA -39.26%
Short Interest 3.17M
Perf Year 83.05%
Cash/sh 3.15
P/C 8.12
EPS next 5Y 21.00%
ROE -50.37%
52W Range 9.90 - 25.61
Perf YTD 58.65%
Dividend Est. -
P/FCF -
EPS past 5Y 4.07%
ROI -56.42%
52W High -0.08%
Beta 0.20
Dividend TTM -
Quick Ratio 3.94
Sales past 5Y 51.62%
Gross Margin 93.26%
52W Low 158.48%
ATR (14) 0.20
Dividend Ex-Date -
Current Ratio 4.19
EPS Y/Y TTM 5.92%
Oper. Margin -118.09%
RSI (14) 85.58
Volatility 0.13% 0.17%
Employees 355
Debt/Eq 0.08
Sales Y/Y TTM 26.51%
Profit Margin -108.86%
Recom 2.75
Target Price 26.34
Option/Short Yes / No
LT Debt/Eq 0.07
EPS Q/Q 14.02%
Payout -
Rel Volume 0.00
Prev Close 25.59
Sales Surprise -0.31%
EPS Surprise 6.42%
Sales Q/Q 34.55%
Earnings May 01
Avg Volume 1.85M
Price 25.59
SMA20 0.32%
SMA50 20.33%
SMA200 61.93%
Trades
Volume 0
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed
JP Morgan
Neutral
$14
Oct-30-23 Upgrade
Piper Sandler
Neutral → Overweight
$23
Aug-10-23 Upgrade
Stifel
Hold → Buy
$14 → $20
Jan-04-23 Upgrade
Guggenheim
Neutral → Buy
$22
Aug-29-22 Initiated
Cowen
Outperform
$25
Aug-05-22 Upgrade
JMP Securities
Mkt Perform → Mkt Outperform
$23
Feb-28-22 Downgrade
Barclays
Equal Weight → Underweight
$11 → $6
Nov-08-21 Downgrade
Stifel
Buy → Hold
$60 → $10
Nov-08-21 Downgrade
Canaccord Genuity
Buy → Hold
$72 → $12
Nov-08-21 Downgrade
Barclays
Overweight → Equal Weight
$50 → $11
Nov-05-21 Downgrade
Truist
Buy → Hold
$65 → $10
Sep-30-21 Resumed
Stifel
Buy
$60
Mar-31-21 Initiated
Credit Suisse
Outperform
$78
Feb-10-21 Upgrade
SVB Leerink
Mkt Perform → Outperform
$70
Dec-03-20 Initiated
Stifel
Buy
$75
Sep-14-20 Resumed
JP Morgan
Neutral
$52
May-07-20 Downgrade
Nomura
Buy → Neutral
$84 → $60
Mar-04-20 Initiated
Barclays
Overweight
$70
Dec-20-19 Reiterated
Jefferies
Buy
$53 → $77
Oct-29-19 Upgrade
SVB Leerink
Underperform → Mkt Perform
$29 → $34
Show Previous Ratings
Jun-11-24 08:30AM
Jun-03-24 07:00AM
May-23-24 01:15PM
May-10-24 01:54PM
09:30AM
08:50AM
Loading…
08:50AM
Apr-30-24 07:10AM
07:03AM
07:02AM
07:00AM
03:41AM
Apr-29-24 02:36PM
02:17PM
01:41PM
01:02PM
(Pharmaceutical Technology)
12:17PM
Loading…
12:17PM
12:16PM
11:19AM
10:46AM
10:33AM
09:57AM
09:02AM
08:54AM
07:29AM
07:29AM
07:29AM
07:18AM
07:06AM
07:00AM
Apr-24-24 10:01AM
10:39AM
Loading…
Apr-21-24 10:39AM
Apr-09-24 07:00AM
Mar-07-24 11:31AM
Mar-04-24 08:28PM
Feb-28-24 09:55AM
Feb-27-24 07:00AM
Feb-12-24 09:55AM
Feb-07-24 09:20AM
08:28AM
12:33AM
(Thomson Reuters StreetEvents)
Feb-06-24 07:00AM
Feb-01-24 04:50PM
07:00AM
Jan-30-24 10:01AM
Jan-18-24 11:13AM
Jan-08-24 07:00AM
Jan-05-24 07:00AM
Jan-02-24 07:00AM
Dec-15-23 07:06AM
Dec-02-23 07:08AM
Nov-29-23 11:30AM
07:00AM
Nov-07-23 07:00AM
Nov-01-23 03:03AM
Oct-31-23 07:25AM
04:51AM
(Thomson Reuters StreetEvents)
01:16AM
Oct-30-23 08:15AM
07:01AM
07:00AM
Oct-16-23 12:39PM
Oct-05-23 11:38AM
Sep-29-23 09:00AM
Sep-22-23 12:02PM
11:46AM
Sep-15-23 05:00PM
Sep-08-23 11:30AM
Aug-21-23 07:43PM
Aug-19-23 07:40AM
Aug-18-23 04:05PM
Aug-11-23 03:30PM
Aug-10-23 08:13AM
Aug-09-23 08:50AM
07:00AM
Aug-03-23 04:15PM
Aug-02-23 07:00AM
Jun-09-23 09:02AM
Jun-02-23 11:31AM
May-25-23 05:00PM
May-23-23 07:00AM
May-08-23 01:31PM
07:00AM
May-04-23 05:38AM
May-03-23 08:15AM
07:00AM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
07:00AM
Apr-19-23 07:00AM
Apr-18-23 06:53AM
Mar-23-23 11:30AM
Mar-16-23 05:25PM
Mar-15-23 11:52AM
06:28AM
Mar-14-23 05:53PM
05:32PM
04:26AM
Mar-09-23 11:30AM
Mar-01-23 07:00AM
Feb-27-23 07:00AM
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera's switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kelly Thomas Patrick Chief Financial Officer Feb 16 '24 Sale 15.62 3,010 47,009 80,350 Feb 20 04:05 PM Sherman Matthew L EVP & Chief Medical Officer Feb 16 '24 Sale 15.62 2,615 40,840 108,739 Feb 20 04:06 PM Pitman Jama SVP, Chief Development Officer Feb 16 '24 Sale 15.62 2,267 35,405 68,031 Feb 20 04:05 PM Martin Daniel C. Chief Commercial Officer Feb 16 '24 Sale 15.62 2,267 35,405 55,118 Feb 20 04:05 PM Kelly Thomas Patrick Chief Financial Officer Jan 16 '24 Sale 14.47 2,435 35,234 66,085 Jan 18 04:15 PM Sherman Matthew L EVP & Chief Medical Officer Jan 16 '24 Sale 14.47 2,435 35,234 94,079 Jan 18 04:15 PM Pitman Jama SVP, Chief Development Officer Jan 16 '24 Sale 14.47 1,624 23,499 50,573 Jan 18 04:15 PM Martin Daniel C. Chief Commercial Officer Jan 16 '24 Sale 14.47 1,624 23,499 47,660 Jan 18 04:15 PM Hoerter Steven L. President and CEO Dec 13 '23 Sale 15.37 30,664 471,217 72,763 Dec 14 04:05 PM Kelly Thomas Patrick Chief Financial Officer Dec 13 '23 Sale 15.37 2,792 42,905 68,520 Dec 14 04:05 PM Sherman Matthew L EVP & Chief Medical Officer Dec 13 '23 Sale 15.37 2,792 42,905 96,514 Dec 14 04:05 PM Martin Daniel C. Chief Commercial Officer Dec 13 '23 Sale 15.37 1,727 26,539 49,284 Dec 14 04:05 PM Pitman Jama See Remarks Dec 13 '23 Sale 15.37 1,662 25,540 52,197 Dec 14 04:05 PM Martin Daniel C. Chief Commercial Officer Nov 30 '23 Sale 12.57 17,801 223,755 45,435 Dec 01 04:05 PM Hoerter Steven L. President and CEO Oct 30 '23 Sale 12.02 21,573 259,256 40,927 Oct 31 04:09 PM Sherman Matthew L EVP & Chief Medical Officer Oct 30 '23 Sale 12.02 2,360 28,362 90,628 Oct 31 04:11 PM Kelly Thomas Patrick Chief Financial Officer Oct 30 '23 Sale 12.02 2,316 27,833 63,068 Oct 31 04:09 PM Martin Daniel C. Chief Commercial Officer Oct 30 '23 Sale 12.02 1,407 16,909 62,884 Oct 31 04:10 PM Pitman Jama See Remarks Oct 30 '23 Sale 12.02 1,407 16,909 48,283 Oct 31 04:10 PM Sherman Matthew L EVP & Chief Medical Officer Oct 02 '23 Sale 12.68 2,942 37,305 84,744 Oct 04 04:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite